Press Releases

 
Press Releases
  Date Title and Summary View
Sep 13, 2017
FREMONT, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, presented data from its pivotal Phase 2/3 ZOTRIP study evaluating M2...
Aug 28, 2017
US Patent Office has Published Patent Application for M207 Zolmitriptan Delivered Intracutaneously via Zosano's Proprietary Adhesive Dermally-Applied Microarray (ADAM) Technology FREMONT, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) a clinical sta...
Aug 10, 2017
John Walker appointed permanent CEO at Zosano FREMONT, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive D...
Aug 2, 2017
FREMONT, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today announced that it will host a conference call and w...
Jul 31, 2017
FREMONT, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Inc. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray ("ADAM") technology, announced tod...
Jun 26, 2017
Confirmation of previously announced design of Long-term Safety StudyRecently completed ZOTRIP study acknowledged sufficient for NDA filingCMC development strategy confirmed adequate for registration FREMONT, Calif., June 26, 2017 (GLOBE NEWSW...
Jun 14, 2017
FREMONT, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, today announced that it has approved inducement option grants to two new empl...
Jun 12, 2017
FREMONT, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Inc. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, presented additional data from its pivotal Phase 2/3 ZOTRIP study eval...
Jun 1, 2017
Late-Breaking Oral and Oral Presentations to feature M207 Acute Migraine Therapy Zotrip Pivotal Trial Data Selected by Headache Society and Drug Delivery Meetings FREMONT, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a specialty ...
May 9, 2017
Pivotal trial of M207 meets co-primary endpoints to establish fast and durable pain relief$29.3 million follow-on offering of common stock provides funding for initiating required safety study and meeting pre-commercialization CMC/ manufacturing criteriaZosano names John P. Walker Interim CEO...
Page:
1
... NextLast
= add release to Briefcase